Antifungal hypersensitivity reactions and cross-reactivity patterns
暂无分享,去创建一个
[1] J. Trubiano,et al. Asystolic cardiac arrest following liposomal amphotericin B infusion: anaphylaxis or compliment activation-related pseudoallergy? , 2021, Allergy, Asthma & Clinical Immunology.
[2] F. Queiroz-Telles,et al. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections , 2021, Infectious Diseases and Therapy.
[3] Andrew Gibson,et al. An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity , 2021, Frontiers in Pharmacology.
[4] Michelle C. Maciag,et al. Successful Rapid Desensitization to Micafungin in a Pediatric Patient. , 2020, Pediatric allergy, immunology, and pulmonology.
[5] B. Piraccini,et al. Delayed access and provision of dermatological care as a collateral damage of COVID‐19‐related fear: Allergic contact dermatitis to fluconazole , 2020, Contact dermatitis.
[6] E. Phillips,et al. Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go? , 2020, The journal of allergy and clinical immunology. In practice.
[7] M. Castells,et al. Practical Guidelines for the Evaluation and Management of Drug Hypersensitivity: General Concepts. , 2020, The journal of allergy and clinical immunology. In practice.
[8] S. Wakelin,et al. Fluconazole‐induced fixed drug eruption confirmed by extemporaneous patch testing , 2020, Contact dermatitis.
[9] G. Thompson,et al. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments , 2020, Journal of fungi.
[10] J. Militello. Allergic , 2007, Definitions.
[11] F. Guarneri,et al. Onychomadesis secondary to allergic contact dermatitis to tioconazole contained in a nail lacquer: Description of three cases , 2019, Contact dermatitis.
[12] M. Slavin,et al. Azole antifungals and new targeted therapies for hematological malignancy. , 2019, Current opinion in infectious diseases.
[13] S. Lekshmi,et al. Case report on Fluconazole Induced stevens -Johnson Syndrome , 2019, Research Journal of Pharmacy and Technology.
[14] Young Keun Kim,et al. Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[15] M. Pirmohamed,et al. Controversies in drug allergy: Testing for delayed reactions. , 2019, The Journal of allergy and clinical immunology.
[16] L. Schneller-Pavelescu,et al. Allergic contact dermatitis caused by undecylenic acid in an antifungal nail solution , 2018, Contact dermatitis.
[17] M. Pastor-Nieto,et al. Is tioconazole contact dermatitis still a concern? Bringing allergic contact dermatitis caused by topical tioconazole back into the spotlight , 2018, Contact dermatitis.
[18] Jiezhun Gu,et al. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. , 2018, Journal of hepatology.
[19] S. Demir,et al. Generalized Fixed Drug Eruption Induced by Fluconazole Without Cross-Reactivity to Itraconazole: Lymphocyte Transformation Test Confirms the Diagnosis , 2018, Drug Safety - Case Reports.
[20] C. Harris,et al. Graded isavuconazole introduction in a patient with voriconazole allergy , 2017, Transplant infectious disease : an official journal of the Transplantation Society.
[21] S. Seo,et al. Antifungal stewardship considerations for adults and pediatrics , 2017, Virulence.
[22] P. Smuszkiewicz,et al. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients , 2017, Infection.
[23] J. Ziegler,et al. Desensitisation to liposomal amphotericin B. , 2017, The journal of allergy and clinical immunology. In practice.
[24] E. Bouza,et al. The current treatment landscape: the need for antifungal stewardship programmes. , 2016, The Journal of antimicrobial chemotherapy.
[25] A. Heidari,et al. Cross‐reactivity between voriconazole, fluconazole and itraconazole , 2016, Journal of clinical pharmacy and therapeutics.
[26] P. McMahon,et al. Probable Griseofulvin‐Induced Drug Reaction with Eosinophilia and Systemic Symptoms in a Child , 2016, Pediatric dermatology.
[27] D. Kearney,et al. Griseofulvin associated with drug reaction with eosinophilia and systemic symptoms (DRESS) , 2016, JAAD case reports.
[28] D. Andes,et al. A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications , 2015 .
[29] T. Jean,et al. Successful desensitization of voriconazole in an immunosuppressed pediatric patient. , 2015, The journal of allergy and clinical immunology. In practice.
[30] W. Kern,et al. Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany , 2015, Infection.
[31] R. Kumar,et al. Fluconazole-induced Stevens-Jonson syndrome - , 2014 .
[32] P. Demoly,et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper , 2013, Allergy.
[33] H. Maibach,et al. The skin prick test – European standards , 2013, Clinical and Translational Allergy.
[34] T. Kestenbaum,et al. Two cases of acute generalized exanthematous pustulosis related to oral terbinafine and an analysis of the clinical reaction pattern. , 2012, Dermatology online journal.
[35] J. George,et al. Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection , 2012, Journal of pharmacology & pharmacotherapeutics.
[36] M. Narra,et al. Desensitization to Liposomal Amphotericin B after Anaphylactic Reaction , 2012 .
[37] Yechezkel Barenholz,et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[38] M. B. Maheshwari,et al. A diagnostic challenge: acute generalized exanthematous pustulosis or pustular psoriasis due to terbinafine , 2012, Clinical and experimental dermatology.
[39] S. Georgiou,et al. Short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients. , 2011, Journal of drugs in dermatology : JDD.
[40] M. Sánchez-Borges,et al. Fixed drug eruptions induced by cross-reactive imidazoles. , 2011, Allergologia et immunopathologia.
[41] S. Jariwala,et al. A novel method of desensitization for fluconazole hypersensitivity in a patient with AIDS. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[42] Joint Task Force on Practice Parameters. Drug allergy: an updated practice parameter. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[43] A. Dunant,et al. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.
[44] Chun-Hua Wang,et al. Caspofungin-induced severe toxic epidermal necrolysis. , 2010, The Annals of pharmacotherapy.
[45] David M. Lang,et al. Drug allergy: an updated practice parameter. , 2010 .
[46] R. Corrêa-Oliveira,et al. Acute generalized exanthematous pustulosis induced by itraconazole: an immunological approach , 2009, Clinical and experimental dermatology.
[47] Uchenna R. Ofoma,et al. Fluconazole induced toxic epidermal necrolysis: a case report , 2009, Cases journal.
[48] M. Rad,et al. Fixed drug eruption resulting from fluconazole use: a case report , 2009, Journal of medical case reports.
[49] A. Vacca,et al. Maculopapular rash due to fluconazole , 2009, Clinical and experimental dermatology.
[50] L. Tanno,et al. Ketoconazole Allergy , 2009, Clinics.
[51] G. Alangaden,et al. Immediate cross-hypersensitivity between Micafungin and Caspofungin: A case report , 2009, Journal of Oncology Pharmacy Practice.
[52] Peng Yang,et al. Appearance of Anaphylactic Shock after Long-Term Intravenous Itraconazole Treatment , 2009, The Annals of pharmacotherapy.
[53] R. Chan,et al. Lack of Allergic Cross-Reactivity between Fluconazole and Voriconazole , 2009, Antimicrobial Agents and Chemotherapy.
[54] C. Randolph,et al. Rapid desensitization to fluconazole (Diflucan). , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[55] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[56] S. Georgiou,et al. Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient. , 2008, Acta dermato-venereologica.
[57] D. Hillaire‐buys,et al. Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.
[58] A. Bircher,et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature , 2005, The British journal of dermatology.
[59] K. de With,et al. Hospital use of systemic antifungal drugs , 2005, BMC clinical pharmacology.
[60] A. Goel,et al. Fluconazole Induced Fixed Drug Eruption: A Rare Offender , 2004, The Journal of dermatology.
[61] H. S. Earl,et al. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. , 2003, The Journal of allergy and clinical immunology.
[62] J. Cleary,et al. Effects of Amphotericin B and Caspofungin on Histamine Expression , 2003, Pharmacotherapy.
[63] J. Lane,et al. Fixed drug eruption due to fluconazole. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[64] L. Dubertret,et al. [Acute generalized exanthematous pustulosis induced by drugs with low-digestive absorption: acarbose and nystatin]. , 2003, Annales de dermatologie et de venereologie.
[65] A. Krol,et al. Acute generalized exanthematous pustulosis induced by oral fluconazole , 2002, Journal of cutaneous medicine and surgery.
[66] B. Albes,et al. [Acute generalized exanthematous pustulosis due to fluconazole]. , 2002, Annales de dermatologie et de venereologie.
[67] A. Iwamoto,et al. Desensitization to Fluconazole in an AIDS Patient , 2001, The Annals of pharmacotherapy.
[68] A. Hall,et al. Acute generalized exanthematous pustulosis associated with oral terbinafine , 2000, The Australasian journal of dermatology.
[69] S. Halevy,et al. Generalized pustular drug eruptions: confirmation by in vitro tests , 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.
[70] L. D. De Raeve,et al. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. , 1997, Journal of the American Academy of Dermatology.
[71] Y. M. Park,et al. Acute generalized exanthematous pustulosis induced by itraconazole. , 1997, Journal of the American Academy of Dermatology.
[72] N. Dupin,et al. Acute generalized exanthematous pustulosis induced by terbinafine. , 1996, Archives of dermatology.
[73] M. Gonçalo,et al. Allergic contact dermatitis from tioconazole , 1996, Contact dermatitis.
[74] S. Reitamo,et al. A study of 72 patients with contact allergy to tioconazole , 1996, The British journal of dermatology.
[75] R. Lockey,et al. Amphotericin B: emergency challenge in a neutropenic, asthmatic patient with fungal sepsis. , 1995, The Journal of allergy and clinical immunology.
[76] M. Matura,et al. Contact allergy to imidazoles used as antimycotic agents , 1995, Contact dermatitis.
[77] W. Heymann,et al. Itraconazole-induced acute generalized exanthemic pustulosis. , 1995, Journal of the American Academy of Dermatology.
[78] T. Casale,et al. Report of successful desensitization to itraconazole. , 1994, The Journal of allergy and clinical immunology.
[79] G. Murphy,et al. Allergic contact dermatitis from tioconazole without cross‐sensitivity to other imidazoles , 1994, Contact dermatitis.
[80] J. Saurat,et al. Contact dermatitis from tioconazole mimicking “one hand two feet syndrome” , 1993, Contact dermatitis.
[81] J. Vilaplana,et al. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection. , 1993, Dermatology.
[82] S. Reitamo,et al. Contact allergy to tioconazole , 1992, Contact dermatitis.
[83] P. Marren,et al. Contact sensitivity to tioconazole and other imidazoles , 1992, Contact dermatitis.
[84] J. Díaz-Pérez,et al. Contact dermatitis from tioconazole with cross‐sensitivity to other imidazoles , 1992, Contact dermatitis.
[85] G. Kinghorn,et al. Angio-oedema after fluconazole , 1991, The Lancet.
[86] J. Wout,et al. Stevens-Johnson syndrome after fluconazole , 1991, The Lancet.
[87] G. Neuhaus,et al. Anaphylactic reaction after oral fluconazole. , 1991, BMJ.
[88] H. Baes. Contact sensitivity to miconazole with ortho‐chloro cross‐sensitivity to other imidazoles , 1991, Contact dermatitis.
[89] O. Correia,et al. [Lyell's syndrome and griseofulvin]. , 1991, Annales francaises d'anesthesie et de reanimation.
[90] Stephen K. Jones,et al. Contact dermatitis from tioconazole , 1990, Contact dermatitis.
[91] I. Miyoshi,et al. Anaphylaxis to flucytosine in a patient with AIDS. , 1988, JAMA.
[92] M. Duffill,et al. Toxic epidermal necrolysis from griseofulvin. , 1988, Journal of the American Academy of Dermatology.
[93] H. Haverkamp,et al. Anaphylactic reactions to ketoconazole. , 1983, British medical journal.
[94] N. M. O'farrell. Allergic reaction to griseofulvin. , 1960, Archives of dermatology.